News

100.000 pebrots contra el càncer

divendres i demà dissabte, 3 i 4 de febrer 450 establiments Condis de Catalunya Xantal Llavina, Quim Masferrer Manel Esteller Francesc Mauri Francesc Viñas Pilar Condal més de 600 voluntaris Dr. Manel Esteller

Leer más about 100.000 pebrots contra el càncer

Bastos Medical, committed to IDIBELL’s ovarian cancer research

Each year more than 3,000 new cases of ovarian cancer are diagnosed in Spain, and about 2,000 women die from this disease. This high mortality rate is due in large part to a late diagnosis, made when the disease is advanced, and / or to the lack of accurate treatments. In order to advance in […]

Leer más about Bastos Medical, committed to IDIBELL’s ovarian cancer research

European experts highlight the potential of xenografts in personalized oncology

European research lays the foundation for the development of new and ambitious research projects with xenografts derived from patients, preclinical models with great potential to advance research and treatment in cancer. The review article, published in Nature Reviews Cancer, is the result of the joint work of the European consortium of researchers EurOPDX, which includes […]

Leer más about European experts highlight the potential of xenografts in personalized oncology

A new strategy to improve genetic diagnosis for families with hereditary cancer

Reducing the impact of cancer through genetic diagnosis: new technological challenges New diagnostic strategy published in two papers in Scientific Reports

Leer más about A new strategy to improve genetic diagnosis for families with hereditary cancer

El Hotel Barcelona Princess entrega 16.000€ a la investigación de las enfermedades raras

Hotel Barcelona Princess entrega cheque simbólico de 16.000 € de las donaciones recaudadas al CIBERER Hotel Barcelona Princess lucha contra las enfermedades raras reto solidario 16.000 € CIBERER

Leer más about El Hotel Barcelona Princess entrega 16.000€ a la investigación de las enfermedades raras

Inactivation of the B2M gene is recurrent in lung cancer and may condition the response to immunotherapy

Researchers from the Genes and Cancer research group at the Bellvitge Biomedical Research Institute (IDIBELL) have identified inactivating mutations in a number of genes that code for HLA-I histocompatibility complex proteins, which are involved in the immune response and can condition the tesponse of lung cancer patients to immunotherapy. The study is a result of […]

Leer más about Inactivation of the B2M gene is recurrent in lung cancer and may condition the response to immunotherapy

SB Hotels Tarragona Marathon wants to tear down the wall of childhood cancer

In its 7th edition, the sports test will collect voluntary donations for the investigation of children’s sarcoma that is carried out in the IDIBELL Tear down the wall Run with a 100% charitable race numbers!

Leer más about SB Hotels Tarragona Marathon wants to tear down the wall of childhood cancer

A bronchial GPS based on digital imaging for the early detection of lung cancer

Researchers at the Center for Computer Vision and Bellvitge Hospital – IDIBELL have developed a technology that allows physicians to locate and move around the patients’ bronchi following a planned and localized route thanks to augmented reality techniques, video games and 3D modeling. The objective of this collaboration is to improve the existing technology in […]

Leer más about A bronchial GPS based on digital imaging for the early detection of lung cancer

Gabriel Capellá, director of IDIBELL

appointment of  Dr. Gabriel Capellá as director of IDIBELL.

Leer más about Gabriel Capellá, director of IDIBELL
Scroll to Top